You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
High affinity antagonist of the receptor for advanced glycation end products (RAGE) (Ki = 25 nM). Blocks Aβ binding to the V domain of RAGE and inhibits Aβ40- and Aβ42-induced cellular stress in RAGE-expressing cells in vitro and in the mouse brain in vivo. Blocks β-secretase activity, Aβ production, microglia activation and neuroinflammation in vivo. BBB permeable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 327.85. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.05 mL||15.25 mL||30.5 mL|
|5 mM||0.61 mL||3.05 mL||6.1 mL|
|10 mM||0.31 mL||1.53 mL||3.05 mL|
|50 mM||0.06 mL||0.31 mL||0.61 mL|
References are publications that support the biological activity of the product.
Deane et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid beta -mediated brain disorder in a mouse model of Alzheimer disease. J.Clin.Invest. 122 1377 PMID: 22406537
Hong et al (2016) Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-beta Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus. Neurochem.Res. 41 1192 PMID: 26738988
If you know of a relevant reference for FPS ZM1, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: FPS ZM1, FPS ZM1 supplier, FPSZM1, Inhibitors, Inhibits, Antagonist, RAGE, Receptor, for, advanced, glycation, end, products, RAP, antagonist, peptide, blood-brain, barrier, BBB, permeable, penetrant, AB42, Aβ, Aβ42, Alzheimer's, Disease, NF-kB/IkB, 6237, Tocris Bioscience
Citations for FPS ZM1
Citations are publications that use Tocris products.
Currently there are no citations for FPS ZM1. Do you know of a great paper that uses FPS ZM1 from Tocris? Please let us know.
Reviews for FPS ZM1
There are currently no reviews for this product. Be the first to review FPS ZM1 and earn rewards!
Have you used FPS ZM1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.